QQQ   417.55 (-1.38%)
AAPL   164.95 (-1.25%)
MSFT   401.13 (-0.78%)
META   487.97 (-2.76%)
GOOGL   154.75 (-0.81%)
AMZN   176.23 (-1.67%)
TSLA   149.30 (-0.42%)
NVDA   817.98 (-3.39%)
AMD   148.63 (-4.16%)
NIO   3.83 (-4.25%)
BABA   68.70 (-0.26%)
T   16.35 (+0.12%)
F   12.12 (+0.50%)
MU   107.54 (-3.92%)
GE   149.23 (-2.43%)
CGC   7.95 (+1.53%)
DIS   111.64 (-0.70%)
AMC   3.19 (+9.25%)
PFE   25.82 (+1.69%)
PYPL   61.95 (-0.24%)
XOM   120.16 (+1.38%)
QQQ   417.55 (-1.38%)
AAPL   164.95 (-1.25%)
MSFT   401.13 (-0.78%)
META   487.97 (-2.76%)
GOOGL   154.75 (-0.81%)
AMZN   176.23 (-1.67%)
TSLA   149.30 (-0.42%)
NVDA   817.98 (-3.39%)
AMD   148.63 (-4.16%)
NIO   3.83 (-4.25%)
BABA   68.70 (-0.26%)
T   16.35 (+0.12%)
F   12.12 (+0.50%)
MU   107.54 (-3.92%)
GE   149.23 (-2.43%)
CGC   7.95 (+1.53%)
DIS   111.64 (-0.70%)
AMC   3.19 (+9.25%)
PFE   25.82 (+1.69%)
PYPL   61.95 (-0.24%)
XOM   120.16 (+1.38%)
QQQ   417.55 (-1.38%)
AAPL   164.95 (-1.25%)
MSFT   401.13 (-0.78%)
META   487.97 (-2.76%)
GOOGL   154.75 (-0.81%)
AMZN   176.23 (-1.67%)
TSLA   149.30 (-0.42%)
NVDA   817.98 (-3.39%)
AMD   148.63 (-4.16%)
NIO   3.83 (-4.25%)
BABA   68.70 (-0.26%)
T   16.35 (+0.12%)
F   12.12 (+0.50%)
MU   107.54 (-3.92%)
GE   149.23 (-2.43%)
CGC   7.95 (+1.53%)
DIS   111.64 (-0.70%)
AMC   3.19 (+9.25%)
PFE   25.82 (+1.69%)
PYPL   61.95 (-0.24%)
XOM   120.16 (+1.38%)
QQQ   417.55 (-1.38%)
AAPL   164.95 (-1.25%)
MSFT   401.13 (-0.78%)
META   487.97 (-2.76%)
GOOGL   154.75 (-0.81%)
AMZN   176.23 (-1.67%)
TSLA   149.30 (-0.42%)
NVDA   817.98 (-3.39%)
AMD   148.63 (-4.16%)
NIO   3.83 (-4.25%)
BABA   68.70 (-0.26%)
T   16.35 (+0.12%)
F   12.12 (+0.50%)
MU   107.54 (-3.92%)
GE   149.23 (-2.43%)
CGC   7.95 (+1.53%)
DIS   111.64 (-0.70%)
AMC   3.19 (+9.25%)
PFE   25.82 (+1.69%)
PYPL   61.95 (-0.24%)
XOM   120.16 (+1.38%)
NASDAQ:VIR

Vir Biotechnology (VIR) Stock Price, News & Analysis

$7.93
-0.03 (-0.38%)
(As of 11:58 AM ET)
Today's Range
$7.93
$8.21
50-Day Range
$7.96
$11.90
52-Week Range
$7.72
$27.48
Volume
194,339 shs
Average Volume
1.03 million shs
Market Capitalization
$1.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.38

Vir Biotechnology MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.57 Rating Score
Upside/​Downside
320.7% Upside
$34.38 Price Target
Short Interest
Healthy
5.63% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.06mentions of Vir Biotechnology in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$1.53 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.04) to ($3.87) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.61 out of 5 stars

Medical Sector

443rd out of 918 stocks

Biological Products, Except Diagnostic Industry

65th out of 154 stocks

VIR stock logo

About Vir Biotechnology Stock (NASDAQ:VIR)

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.

VIR Stock Price History

VIR Stock News Headlines

New crypto project uncovers 2,050% in 65 days
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
Vir Biotechnology Inc
New crypto project uncovers 2,050% in 65 days
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
VIR Jul 2024 17.500 call
Vir Biotechnology, Inc. (VIR)
VIR Oct 2024 20.000 call
3 Highly Rated Biotech Stocks to Buy for 300% Gains
See More Headlines
Receive VIR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vir Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
4/19/2024
Next Earnings (Confirmed)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:VIR
Fax
N/A
Employees
587
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$34.38
High Stock Price Target
$110.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+329.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

Net Income
$-615,060,000.00
Net Margins
-713.69%
Pretax Margin
-728.93%

Debt

Sales & Book Value

Annual Sales
$86.18 million
Book Value
$11.82 per share

Miscellaneous

Free Float
110,156,000
Market Cap
$1.08 billion
Optionable
Optionable
Beta
0.41
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Dr. Ann M. Hanly Ph.D. (Age 53)
    Executive VP & Chief Technology Officer
    Comp: $842.23k
  • Dr. Phillip Pang M.D. (Age 48)
    Ph.D., Executive VP & Chief Medical Officer
    Comp: $837.38k
  • Dr. Marianne De Backer M.B.A. (Age 54)
    M.Sc., Ph.D., CEO & Director
  • Dr. Klaus Frueh Ph.D. (Age 64)
    Co-Founder & Scientific Advisor
    Comp: $177.66k
  • Dr. Lawrence Corey M.D. (Age 76)
    Co-Founder & Scientific Advisor
  • Dr. Louis J. Picker M.D.
    Co-Founder & Scientific Advisor
  • Mr. Sung H. Lee (Age 54)
    Executive VP & CFO
  • Dr. Jennifer Eileen Towne Ph.D.
    Executive VP & Chief Scientific Officer
  • Ms. Heather Rowe Armstrong
    Vice President of Investor Relations
  • Ms. Vanina De Verneuil J.D.
    Executive VP, General Counsel & Corporate Secretary

VIR Stock Analysis - Frequently Asked Questions

Should I buy or sell Vir Biotechnology stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vir Biotechnology in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VIR shares.
View VIR analyst ratings
or view top-rated stocks.

What is Vir Biotechnology's stock price target for 2024?

7 equities research analysts have issued 12-month price targets for Vir Biotechnology's shares. Their VIR share price targets range from $10.00 to $110.00. On average, they anticipate the company's stock price to reach $34.38 in the next year. This suggests a possible upside of 320.7% from the stock's current price.
View analysts price targets for VIR
or view top-rated stocks among Wall Street analysts.

How have VIR shares performed in 2024?

Vir Biotechnology's stock was trading at $10.06 at the beginning of the year. Since then, VIR shares have decreased by 18.8% and is now trading at $8.17.
View the best growth stocks for 2024 here
.

When is Vir Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our VIR earnings forecast
.

How can I listen to Vir Biotechnology's earnings call?

Vir Biotechnology will be holding an earnings conference call on Thursday, May 2nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Vir Biotechnology's earnings last quarter?

Vir Biotechnology, Inc. (NASDAQ:VIR) posted its earnings results on Thursday, February, 22nd. The company reported ($0.86) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.14) by $0.28. The business earned $16.80 million during the quarter, compared to the consensus estimate of $11.18 million. Vir Biotechnology had a negative net margin of 713.69% and a negative trailing twelve-month return on equity of 34.92%. The company's quarterly revenue was down 66.0% on a year-over-year basis. During the same period last year, the company earned ($0.76) EPS.

What ETFs hold Vir Biotechnology's stock?
What is George Scangos' approval rating as Vir Biotechnology's CEO?

7 employees have rated Vir Biotechnology Chief Executive Officer George Scangos on Glassdoor.com. George Scangos has an approval rating of 85% among the company's employees.

When did Vir Biotechnology IPO?

Vir Biotechnology (VIR) raised $149 million in an IPO on Friday, October 11th 2019. The company issued 7,100,000 shares at $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays acted as the underwriters for the IPO.

Who are Vir Biotechnology's major shareholders?

Vir Biotechnology's stock is owned by many different retail and institutional investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.03%), Ballentine Partners LLC (0.01%) and GAMMA Investing LLC (0.00%). Insiders that own company stock include Ann M Hanly, Backer Marianne De, Charles Elliott Sigal, Endurance (Cayman) Ltd Svf, George A Scangos, Herbert Virgin, Howard Horn, Janet Napolitano, Johanna Friedl-Naderer, Medpace Investors, Llc, Phillip Pang, Robert J More, Robert J More, Saira Ramasastry, Steven J Rice, Sung Lee, Vicki L Sato and Vicki L Sato.
View institutional ownership trends
.

How do I buy shares of Vir Biotechnology?

Shares of VIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VIR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners